Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well sunitinib malate works in treating patients with
endometrial cancer that has come back after a period of improvement (recurrent) or has spread
to other places in the body (metastatic). Sunitinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.